查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1725960

前糖尿病市場:現狀分析及預測(2025年～2033年)

Prediabetes Market: Current Analysis and Forecast (2025-2033)
出版日期: | 出版商: UnivDatos Market Insights Pvt Ltd | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

糖尿病前期是指患者出現類似糖尿病的症狀，例如血糖值高於正常範圍但低於第2型糖尿病的診斷閾值。根據美國糖尿病協會 (ADA) 的定義，糖尿病前期是指糖化血紅蛋白 (A1C) 檢測結果在 5.7% 至 6.4% 之間的疾病。糖尿病前期會導致血糖耐受性差或胰島素敏感性降低，可能導致糖尿病、心臟病和中風。糖尿病前期可能沒有明顯的症狀，因此可能在數年內都難以察覺，需要定期檢查。糖尿病前期的症狀包括肥胖、缺乏運動、不良飲食、遺傳因素和老化。因此，健康的糖尿病前期飲食、規律的體能活動和減重有助於預防糖尿病，尤其是在確診糖尿病前期之後。

預計在預測期內（2025-2033），糖尿病前期市場規模將以約10.02%的速度成長。由於糖尿病前期盛行率的上升、人們對該疾病認識的不斷提高以及全球預防醫學趨勢的變化，糖尿病前期市場正在顯著發展。久坐的生活方式、不合理的飲食和日益增長的肥胖是導致糖尿病前期患病率上升的新因素，尤其是在城市地區。越來越多的人意識到，未經治療的糖尿病前期會導致危險的後果，例如發展為第2型糖尿病和心血管疾病，這鼓勵患者採取早期幹預策略。此外，頻繁的健康檢查和改善生活方式是政府和其他醫療相關機構持續鼓勵的兩個方面，推動市場的成長。

按產品類型劃分，市場細分為診斷和設備、藥品和治療劑、營養補充劑和功能性食品以及其他。其中，診斷和設備領域佔據最高的市場佔有率。這種主導地位源於糖尿病早期檢測工具的不斷增多，人們對糖尿病前期藥物治療和管理意識的不斷提升，以及血糖監測儀、糖化血紅蛋白 (HbA1c) 檢測試劑盒和連續血糖監測 (CGM) 設備的日益普及。然而，由於人們轉向使用天然保健解決方案，以及使用營養保健食品和功能性食品來控制血糖，預計未來幾年營養保健食品和功能性食品領域將以最快的速度成長。

依年齡段，市場分為兒童、成人和老年人。其中，成人市場佔有最大的市場佔有率。這是因為成年人口久坐不動、食用不健康食品且壓力水平較高，增加了患糖尿病前期的風險。然而，老年人口市場成長最快。由於年齡是糖耐量受損和胰島素抗性的常見預測指標，預計全球老年人口的增長將推動糖尿病前期治療的發展。

根據最終用戶，全球市場細分為醫院和診所、診斷中心、家庭護理機構和其他。其中，醫院和診所佔據最大的市場佔有率。主要因素包括患者就診量增加、設備齊全的診斷實驗室的普及以及擅長早期發現和控製糖尿病前期的醫療保健從業人員的增多。然而，預計未來家庭醫療保健領域將呈現最高的複合年增長率。這得益於個人健康監測設備的使用增加、預防醫學知識的普及以及遠距醫療和遠端患者監測設施的發展。

為了更了解糖尿病前期治療方案的市場採用情況，我們根據北美（美國、加拿大等）、歐洲（德國、英國、法國、西班牙、義大利等）、亞太地區（中國、日本、印度等）和世界其他地區的全球採用情況對市場進行了分析。其中，北美由於其高發病率、完善的醫療基礎設施以及政府大力推廣早期篩檢和預防醫學的舉措，佔據了主要的市場佔有率。然而，由於快速的城市化、肥胖率的上升、生活方式的改變以及醫療保健投資的增加，亞太地區的糖尿病前期市場正在蓬勃發展。

推動市場發展的主要公司包括Abbott Laboratories，F． Hoffmann-La Roche Ltd.，Siemens Healthineers，Ascensia Diabetes Care，Omada Health，Noom, Inc.，Eli Lilly and Company，PharmaLinea，Oramed，Bayer 有AG等。

本報告提供全球前糖尿病市場相關調查，市場概要，以及各產品類型，各年齡層，各終端用戶，各地區的趨勢，及加入此市場的主要企業簡介等資訊。

目錄

第1章 市場簡介

第2章 調查手法或假設

第3章 摘要整理

第4章 市場動態

  • 促進因素
  • 機會
  • 阻礙因素
  • 趨勢
  • PESTEL分析
  • 需求面分析
  • 供給方面分析

第5章 價格分析

  • 地區價格分析
  • 價格的影響因素

第6章 全球前糖尿病市場收益(100萬美元)，2023年～2033年預測

第7章 各產品類型市場分析

  • 診斷及設備
  • 醫藥品及治療藥
  • 營養補充品和機能性食品
  • 其他

第8章 各年齡層市場分析

  • 兒童
  • 大人
  • 老年人

第9章 各終端用戶市場分析

  • 醫院·診療所
  • 診斷中心
  • 居家照護
  • 其他

第10章 各地區市場分析

  • 北美
    • 美國
    • 加拿大
    • 其他
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他
  • 其他的國家

第11章 價值鏈分析

  • 限制分析
  • 市場參與企業清單

第12章 競爭情形

  • 競爭儀表板
  • 競爭的市場定位分析
  • 波特五力分析

第13章 企業簡介

  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthineers
  • Ascensia Diabetes Care
  • Omada Health
  • Noom, Inc.
  • Eli Lilly and Company
  • PharmaLinea
  • Oramed
  • Bayer AG

第14章 縮寫與假設

第15章 附錄

簡介目錄
Product Code: UMHE213267

Prediabetes is a diabetes-like condition in which the prediabetes symptoms include a blood glucose level that is above the normal range but below the thresholds considered indicative of type 2 diabetes. According to the American Diabetes Association (ADA), glycated hemoglobin (A1C) test results between 5.7% and 6.4% come in the prediabetes range. Prediabetes points to poor outcomes of glucose tolerance or even insulin sensitivity, which can lead to the development of diabetes, heart conditions, and stroke. Prediabetes can have no visible signs, and, therefore, individuals may be unaware of the condition for several years and require frequent checkups. Some of the signs of prediabetes are obesity, lack of physical activity, poor diet, heredity, and increasing age. Thus, a healthy prediabetes diet, regular physical activity, and weight loss may help to prevent the development of diabetes, specifically if one has been diagnosed with prediabetes.

The Prediabetes market is set to show a growth rate of about 10.02% during the forecast period (2025-2033F). The prediabetes market is significantly progressing because of the increasing rates of its prevalence, the augmentation of awareness about the disease, and the changing trends in the global focus on preventive medicine. A sedentary lifestyle, improper diet, and increased prevalence of obesity have been emerging factors for the rise in the incidence of prediabetes, primarily in urban communities. Growing awareness of the risky consequences of untreated prediabetes, such as the development of type 2 diabetes and cardiovascular diseases, is driving early intervention strategies among patients. Moreover, frequent physical checkups and modifications in lifestyle represent two aspects that governments and other healthcare-related bodies are continuously encouraging, thus driving the market growth.

Based on product type, the market is segmented into diagnostics & devices, pharmaceuticals & therapeutics, nutraceutical & functional foods, and others. Among these, the diagnostics & devices segment has the highest market share. This dominance is due to the growing number of tools for early detection of diabetes, heightened consciousness among people about prediabetes medications and management, and the increased use of blood glucose monitors, HbA1c testing kits, and CGM devices. However, the nutraceuticals & functional foods sector is expected to grow at the fastest rate in the future, due to the shift towards using natural healthcare solutions, and the use of dietary supplements and functional foods to control blood sugar levels.

Based on the age group category, the market is segmented into children, adults, and the elderly. Out of these, the adult segment has the biggest market share. This is because the adult population is engaged in sedentary lifestyles, consumes unhealthy foods, and experiences increased stress levels, which increases the risk of prediabetes. However, the fastest-growing segment is expected to be the elderly segment. Since age is a common predictor of glucose intolerance and insulin resistance, prediabetes treatment is expected to stem from the growing geriatric population across the globe.

Based on the end-user category, the global market is categorized into hospitals & clinics, diagnostic centers, homecare settings, and others. Among these, the hospitals & clinics segment has the largest market share. Major factors are increased patients' visits to hospitals, availability of enhanced diagnostic laboratories, and healthcare practitioners' specialization in early identification and control of prediabetes. However, the Homecare Settings segment is expected to show the highest CAGR in the future. This is due to the increase in the use of personal health monitoring devices, knowledge of preventive care, and developments in telemedicine and remote patient monitoring facilities.

For a better understanding of the market adoption of therapeutics solutions for prediabetes, the market is analyzed based on its worldwide adoption in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Among these, the North America region holds a significant market share due to its high disease prevalence, well-established healthcare infrastructure, and strong government initiatives promoting early screening and preventive care. However, the Asia-Pacific Prediabetes market is moving forward due to rapid urbanization, increasing obesity rates, changing lifestyles, and growing healthcare investments.

Some major players running in the market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers, Ascensia Diabetes Care, Omada Health, Noom, Inc., Eli Lilly and Company, PharmaLinea, Oramed, and Bayer AG.

TABLE OF CONTENTS

1.Market Introduction

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2.Research Methodology or Assumption

  • 2.1. Research Process of the Global Prediabetes Market
  • 2.2. Research Methodology of the Global Prediabetes Market
  • 2.3. Respondent Profile

3.Executive Summary

  • 3.1. Industry Synopsis
  • 3.2. Segmental Outlook
    • 3.2.1. Market Growth Intensity
  • 3.3. Regional Outlook

4.Market Dynamics

  • 4.1. Drivers
  • 4.2. Opportunity
  • 4.3. Restraints
  • 4.4. Trends
  • 4.5. PESTEL Analysis
  • 4.6. Demand Side Analysis
  • 4.7. Supply Side Analysis
    • 4.7.1. Merger & Acquisition
    • 4.7.2. Collaboration & Investment Scenario
    • 4.7.3. Industry Insights: Leading Startups and Their Unique Strategies

5.Pricing Analysis

  • 5.1. Regional Pricing Analysis
  • 5.2. Price Influencing Factors

6.Global Prediabetes Market Revenue (USD Mn), 2023-2033F

7.Market Insights By Product Type

  • 7.1. Diagnostics & Devices
  • 7.2. Pharmaceuticals & Therapeutics
  • 7.3. Nutraceuticals & Functional Foods
  • 7.4. Others

8.Market Insights By Age Group

  • 8.1. Children
  • 8.2. Adults
  • 8.3. Elderly

9.Market Insights By End User

  • 9.1. Hospitals & Clinics
  • 9.2. Diagnostic Centers
  • 9.3. Homecare Settings
  • 9.4. Others

10.Market Insights By Region

  • 10.1. North America
    • 10.1.1. U.S.
    • 10.1.2. Canada
    • 10.1.3. Rest of North America
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. U.K.
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Rest of Asia-Pacific
  • 10.4. Rest of World

11.Value Chain Analysis

  • 11.1. Marginal Analysis
  • 11.2. List of Market Participants

12.Competitive Landscape

  • 12.1. Competition Dashboard
  • 12.2. Competitor Market Positioning Analysis
  • 12.3. Porter Five Forces Analysis

13.Company Profiled

  • 13.1. Abbott Laboratories
    • 13.1.1. Company Overview
    • 13.1.2. Key Financials
    • 13.1.3. SWOT Analysis
    • 13.1.4. Product Portfolio
    • 13.1.5. Recent Developments
  • 13.2. Roche Diagnostics
  • 13.3. Siemens Healthineers
  • 13.4. Ascensia Diabetes Care
  • 13.5. Omada Health
  • 13.6. Noom, Inc.
  • 13.7. Eli Lilly and Company
  • 13.8. PharmaLinea
  • 13.9. Oramed
  • 13.10. Bayer AG

14.Acronyms & Assumption

15.Annexure